Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Status:
Recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of gene-modified immune cells (FH-MCVA2TCR)
and to see how well they work in treating patients with Merkel cell cancer that has spread to
other parts of the body (metastatic) or that cannot be removed by surgery (unresectable).
Placing a gene that has been created in the laboratory into immune cells may improve the
body's ability to fight Merkel cell cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
bluebird bio National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Avelumab Immunoglobulin G Immunoglobulins Pembrolizumab